Cytomos announced the appointment of Dr Fernanda Masri as Chief Commercial and Innovation Officer and Dr Christel Fenge as Techno-Commercial Adviser. In her new role, Fernanda will spearhead Cytomos’ commercialisation strategy, as the company rapidly evolves the technology into a commercial product platform suitable from early R&D and Product Development through to manufacturing, building on the progress over the past decade. The company’s vastly accelerated progress towards bringing its revolutionary technology to market for the benefit of biopharmaceutical and Advanced Therapy Medicinal Products (ATMPS) and their Contract Development and Manufacturing Organisations (CDMOs) marks the start of a seismic disruption to the international single cell, label-free analytical industry through the arrival of AuraCyt™. Dr Christel Fenge will provide valuable input into both market potential and market penetration analysis and the company’s ‘go to market’ strategy.
The company expects CE approval for its brand-new benchtop instrument, Celledonia™ to allow a full market launch in Q2.
Cytomos’s core product – its ground-breaking cell analysis AuraCyt™ platform technology – provides the life science industry with an innovative and simple tool that is set to transform biopharmaceutical discovery and development through its capability to obtain a multitude of data on the intrinsic properties of cells in real-time.
Dr Fernanda Masri served as Head of Innovation Manufacturing and Collaborations at Cell and Gene Therapy Catapult. She worked at Sartorius as a Technology Expert for Regenerative Medicine where she helped to accelerate development and manufacture of cell and gene therapies, making them more readily accessible to patients across the globe. Moreover, as a solutions manager for iPSCs, Fernanda was responsible for developing and implementing a global portfolio of tools and services, specifically geared to iPSC customers. Prior to this, she developed her process engineering skills at the Centre for Commercialization of Regenerative Medicine (CCRM) in Canada.
Dr Christel Fenge previously served as Vice President, R&D Bioprocess at Cytiva with responsibility for upstream and downstream product development and Vice President, Marketing and Product Management Fermentation Technologies at Sartorius. She served as General Manager of Recipharm Biologics, a mid-sized CMO, and held senior management positions in biopharmaceutical development at AstraZeneca. She began her industrial career in cell culture process development at Pharmacia & Upjohn and was involved in the development of RefactoÔ.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!